Paper

Hexa-acylated lipopolysaccharides from the gut microbiota enhance cancer immunotherapy responses

Sardar, Puspendu, Suyama, Satoshi, Imianowski, Charlotte J., Soderholm, Amelia T., Jesus Faustino Ramos, Ruben J., Okkenhaug, Klaus, Bryant, Clare E., Cross, Justin R., Kuo, Paula, Conti, Alberto G., Xia, Wangmingyu, Beresford-Jones, Benjamin S., Shabana, Omar, Whiteside, Sarah K., Pedicord, Virginia A., Tourlomousis, Panagiotis, Wesolowski, Alexander J., Roychoudhuri, Rahul, Evans, Alexander C.

2024

Overview

Immune checkpoint inhibitors (ICI), such as anti-PD-1, have revolutionized cancer treatment, but they are only effective for a minority of patients. The gut microbiome plays a crucial role in modulating immunotherapy treatment responses, and previous studies correlated lipopolysaccharide (LPS)-producing gut microbes with poorer prognosis. However, LPS from diverse bacterial species have activities ranging from immunostimulatory to inhibitory. By functionally analyzing fecal metagenomes from 112 melanoma patients prior to anti-PD-1 therapy, we found that a subset of LPS-producing bacteria encoding immunostimulatory hexa-acylated LPS was enriched in the microbiomes of clinical responders. We confirmed robust activation of the NF-kB pathway by hexa-acylated LPS in vitro, and this activation was significantly inhibited by penta-acylated LPS in a dose-dependent manner. Importantly, oral administration of hexa-acylated LPS augmented anti-PD-1-mediated anti-tumor immunity in an in vivo mouse model of cancer immunotherapy. Microbiome hexa-acylated LPS may therefore represent an accessible predictor and potential enhancer of clinical anti- PD-1 immunotherapy responses. Functional rather than taxonomic profiling of patient gut microbiomes reveals hexa-acylated LPS as a novel biomarker of responsiveness and a targetable pathway for enhancing responses to anti-PD-1, informing future studies and current patient treatment.

• Publisher: Cold Spring Harbor Laboratory
• Subject: Microbiology